WO2020255059A1
|
|
Purification method of carfilzomib
|
WO2020255004A1
|
|
Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof
|
WO2020234817A1
|
|
Polymorphic forms of apalutamide and its preparation thereof
|
WO2020157644A1
|
|
Process for the preparation of amorphous canagliflozin substantially free of hydroperoxide impurity
|
WO2020148641A1
|
|
Process for preparation of 2-amino-5-hydroxy propiophenone
|
WO2020095187A1
|
|
Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
|
WO2020012408A2
|
|
A process for purification of protected polycyclic carbamoylpyridone derivatives
|
WO2019186522A1
|
|
An improved process for preparation of lopinavir and its intermediates thereof
|
WO2019130254A1
|
|
An improved process for 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl) aniline
|
EP3494965A1
|
|
An improved process for the preparation of pirfenidone
|
US2018334434A1
|
|
Process for the preparation and particle size reduction of pirfenidone
|
WO2018229704A1
|
|
Novel polymorphs of eluxadoline and its solvates, process for its preparation and pharmaceutical composition thereof
|
WO2018224957A1
|
|
Novel process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof
|
WO2018167652A1
|
|
Process for preparation of amorphous form of venetoclax
|
US2019375734A1
|
|
Process and crystalline forms of lumacaftor
|
WO2018069833A1
|
|
Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
|
WO2018037350A1
|
|
Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof
|
WO2018029611A1
|
|
Novel processes for preparation of dapagliflozin or its solvates or co-crystals thereof
|
WO2017221189A1
|
|
An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
|
WO2017191608A1
|
|
Novel process for preparation of idelalisib
|